Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Exposing these patients to a medication with even theoretical C-cell proliferative potential is considered unacceptable risk
2.2 GIPR agonism serves to reduce GLP-1R mediated GI AEs in the clinic Treatment with GLP-1R agonists can drive nausea, diarrhea, vomiting, and constipation, which often results in discontinuation of treatment (6-10% of patients) or reduction in dose (~15% of patients) (63)
Randomized controlled trials, observational studies, meta-analyses, and pharmacovigilance reports evaluating GI adverse effects of GLP-1based therapies were included
What This Means The dopamine hit model is not merely incomplete
Representative micrographs and data processing workflows for each structure are shown in Supplementary Fig
